A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK-8294 Monotherapy in Advanced Solid Tumors
Merck Sharp & Dohme LLC
Summary
MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has histologically or cytologically confirmed advanced/metastatic solid tumor; including head and neck squamous cell carcinoma, cervical squamous cell carcinoma, esophageal squamous cell carcinoma, breast cancer (triple negative breast cancer, Estrogen Receptor \[ER\]/progesterone receptor +, human epidermal growth factor receptor 2 negative \[HER2-\]), endometrial, and bladder cancer by pathology report and have previously failed standard treatment, lack standard treatment options, or are intoler…
Interventions
- DrugMK-8294
30 µg via intravenous (IV) infusion
- DrugMK-8294
100 µg via intravenous (IV) infusion
- DrugMK-8294
300 µg via intravenous (IV) infusion
- DrugMK-8294
1 mg via intravenous (IV) infusion
- DrugMK-8294
3 mg via intravenous (IV) infusion
- DrugMK-8294
10 mg via intravenous (IV) infusion
- DrugMK-8294
30 mg via intravenous (IV) infusion
Locations (5)
- Northwestern University ( Site 0101)Chicago, Illinois
- Rambam Health Care Campus ( Site 0201)Haifa
- Sheba Medical Center ( Site 0200)Ramat Gan
- Radboudumc ( Site 0301)Nijmegen, Gelderland
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0300)Amsterdam, North Holland